289 related articles for article (PubMed ID: 27923516)
21. Trends in Clinical Investigation for Myelodysplastic Syndromes.
Prebet T; Zeidan A
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S57-63. PubMed ID: 27521326
[TBL] [Abstract][Full Text] [Related]
22. Moderate increase of secondary hematologic malignancies after myeloablative radiochemotherapy and autologous stem-cell transplantation in patients with indolent lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group.
Lenz G; Dreyling M; Schiegnitz E; Haferlach T; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2004 Dec; 22(24):4926-33. PubMed ID: 15611507
[TBL] [Abstract][Full Text] [Related]
23. A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.
Hu KX; Sun QY; Guo M; Qiao JX; Yu CL; Qiao JH; Dong Z; Sun WJ; Zuo HL; Huang YJ; Cai B; Ai HS
Stem Cells Transl Med; 2016 Apr; 5(4):524-9. PubMed ID: 26838271
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.
Yucel OK; Saliba RM; Rondon G; Ahmed S; Alousi A; Bashir Q; Ciurea SO; Popat U; Khouri I; Marin D; Rezvani K; Kebriaei P; Shpall EJ; Champlin RE; Oran B
Cancer; 2017 Jul; 123(14):2661-2670. PubMed ID: 28324640
[TBL] [Abstract][Full Text] [Related]
25. Myelodysplastic syndromes.
Scott BL; Deeg HJ
Annu Rev Med; 2010; 61():345-58. PubMed ID: 20059342
[TBL] [Abstract][Full Text] [Related]
26. Management of patients with higher risk myelodysplastic syndromes.
Fukumoto JS; Greenberg PL
Crit Rev Oncol Hematol; 2005 Nov; 56(2):179-92. PubMed ID: 15979321
[TBL] [Abstract][Full Text] [Related]
27. [Management of myelodysplastic syndromes].
Duchmann M; Fenaux P; Cluzeau T
Bull Cancer; 2015 Nov; 102(11):946-57. PubMed ID: 26410692
[TBL] [Abstract][Full Text] [Related]
28. Molecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?
Nazha A; Sekeres MA; Gore SD; Zeidan AM
Oncologist; 2015 Sep; 20(9):1069-76. PubMed ID: 26194858
[TBL] [Abstract][Full Text] [Related]
29. [Myelodysplastic syndromes. Diagnosis and therapeutic strategies].
Aul C; Giagounidis A; Germing U; Ganser A
Med Klin (Munich); 2002 Nov; 97(11):666-76. PubMed ID: 12434275
[TBL] [Abstract][Full Text] [Related]
30. Myelodysplastic syndromes: 2011 update on diagnosis, risk-stratification, and management.
Garcia-Manero G
Am J Hematol; 2011 Jun; 86(6):490-8. PubMed ID: 21594886
[TBL] [Abstract][Full Text] [Related]
31. The evolving field of prognostication and risk stratification in MDS: Recent developments and future directions.
Lee EJ; Podoltsev N; Gore SD; Zeidan AM
Blood Rev; 2016 Jan; 30(1):1-10. PubMed ID: 26119927
[TBL] [Abstract][Full Text] [Related]
32. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
33. Recent advances in the management of therapy-related myelodysplastic syndromes and acute myeloid leukemia.
Klimek VM
Curr Opin Hematol; 2013 Mar; 20(2):137-43. PubMed ID: 23343830
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes.
Miller KB
Curr Treat Options Oncol; 2000 Apr; 1(1):63-9. PubMed ID: 12057062
[TBL] [Abstract][Full Text] [Related]
35. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
36. [Secondary myelodysplastic syndrome after autologous transplantation of hematopoietic stem cells in a female patient with Hodgkin's disease].
Stamatović D; Balint B; Marjanović S; Todorović B; Tukić Lj; Malesević M
Vojnosanit Pregl; 2000; 57(5):99-102. PubMed ID: 11213683
[TBL] [Abstract][Full Text] [Related]
37. Advances in the prognostication and management of advanced MDS in children.
Hasle H; Niemeyer CM
Br J Haematol; 2011 Jul; 154(2):185-95. PubMed ID: 21554264
[TBL] [Abstract][Full Text] [Related]
38. High-dose BEAM chemotherapy with autologous haemopoietic stem cell transplantation for Hodgkin's disease is unlikely to be associated with a major increased risk of secondary MDS/AML.
Harrison CN; Gregory W; Hudson GV; Devereux S; Goldstone AH; Hancock B; Winfield D; MacMillan AK; Hoskin P; Newland AC; Milligan D; Linch DC
Br J Cancer; 1999 Oct; 81(3):476-83. PubMed ID: 10507773
[TBL] [Abstract][Full Text] [Related]
39. Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM; Faltas B; Douglas Smith B; Gore S
J Hosp Med; 2013 Jun; 8(6):351-7. PubMed ID: 23666619
[TBL] [Abstract][Full Text] [Related]
40. Porphyria cutanea tarda in a patient with post-transplant MDS.
Oubre D; Cruz J; Keung Y
Bone Marrow Transplant; 2001 Jan; 27(2):219-20. PubMed ID: 11281395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
